468 related articles for article (PubMed ID: 27889038)
1. Treatment of the Primary Tumor in Anal Canal Cancers.
Glynne-Jones R; Rao S
Surg Oncol Clin N Am; 2017 Jan; 26(1):73-90. PubMed ID: 27889038
[TBL] [Abstract][Full Text] [Related]
2. [Management of locally advanced anal canal carcinoma with modulated arctherapy and concurrent chemotherapy].
Troussier I; Huguet F; Servagi-Vernat S; Benahim C; Khalifa J; Darmon I; Ortholan C; Krebs L; Dejean C; Fenoglietto P; Vieillot S; Bensadoun RJ; Thariat J
Cancer Radiother; 2015 Apr; 19(2):127-38. PubMed ID: 25770884
[TBL] [Abstract][Full Text] [Related]
3. Outcomes after intensity-modulated compared with 3-dimensional conformal radiotherapy with chemotherapy for squamous cell carcinoma of the anal canal.
Agarwal MS; Hitchcock KE; Morris CG; George TJ; Mendenhall WM; Zlotecki RA
Curr Oncol; 2019 Aug; 26(4):e515-e521. PubMed ID: 31548820
[TBL] [Abstract][Full Text] [Related]
4. Anal cancer - What is the optimum chemoradiotherapy?
Vinayan A; Glynne-Jones R
Best Pract Res Clin Gastroenterol; 2016 Aug; 30(4):641-53. PubMed ID: 27644911
[TBL] [Abstract][Full Text] [Related]
5. Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal.
Bazan JG; Hara W; Hsu A; Kunz PA; Ford J; Fisher GA; Welton ML; Shelton A; Kapp DS; Koong AC; Goodman KA; Chang DT
Cancer; 2011 Aug; 117(15):3342-51. PubMed ID: 21287530
[TBL] [Abstract][Full Text] [Related]
6. Randomized Clinical Trials in Localized Anal Cancer.
Smith CA; Kachnic LA
Surg Oncol Clin N Am; 2017 Oct; 26(4):705-718. PubMed ID: 28923226
[TBL] [Abstract][Full Text] [Related]
7. Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy.
Kachnic LA; Tsai HK; Coen JJ; Blaszkowsky LS; Hartshorn K; Kwak EL; Willins JD; Ryan DP; Hong TS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):153-8. PubMed ID: 21095071
[TBL] [Abstract][Full Text] [Related]
8. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal.
Kachnic LA; Winter K; Myerson RJ; Goodyear MD; Willins J; Esthappan J; Haddock MG; Rotman M; Parikh PJ; Safran H; Willett CG
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):27-33. PubMed ID: 23154075
[TBL] [Abstract][Full Text] [Related]
9. Combined chemoradiation therapy for anal cancer. A report of 56 cases.
Doci R; Zucali R; Bombelli L; Montalto F; Lamonica G
Ann Surg; 1992 Feb; 215(2):150-6. PubMed ID: 1546901
[TBL] [Abstract][Full Text] [Related]
10. [Results of complex treatment of patients with squamous cell carcinoma of the anal canal using advanced radiotherapy technologies].
Glebovskaya VV; Tkachev SI; Rasulov AO; Tsaryuk VF; Gordeev SS; Fedyanin MY; Aliev VA; Mamedly ZZ; Kuzmichev DV; Trofimova OP; Borisova TN; Yazhgunovich IP
Vopr Onkol; 2015; 61(4):656-60. PubMed ID: 26571840
[TBL] [Abstract][Full Text] [Related]
11. Anal carcinoma therapy: can we improve on 5-fluorouracil/mitomycin/radiotherapy?
Jiang Y; Mackley H; Cheng H; Ajani JA
J Natl Compr Canc Netw; 2010 Jan; 8(1):135-44. PubMed ID: 20064295
[TBL] [Abstract][Full Text] [Related]
12. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of chemoradiotherapy with 5-Fluorouracil and mitomycin C for anal cancer in immunocompetent versus immunodeficient patients.
Seo Y; Kinsella MT; Reynolds HL; Chipman G; Remick SC; Kinsella TJ
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):143-9. PubMed ID: 19203845
[TBL] [Abstract][Full Text] [Related]
14. [Concurrent chemoradiotherapy for squamous cell carcinoma of the anal canal-report of four cases].
Kinjo A; Ogawa K; Iraha S; Tamaki W; Toita T; Kakinohana Y; Samura H; Kinjo I; Nishimaki T; Kuniyoshi Y; Murayama S
Gan To Kagaku Ryoho; 2008 Mar; 35(3):519-22. PubMed ID: 18347409
[TBL] [Abstract][Full Text] [Related]
15. Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
Jones CM; Adams R; Downing A; Glynne-Jones R; Harrison M; Hawkins M; Sebag-Montefiore D; Gilbert DC; Muirhead R
Int J Radiat Oncol Biol Phys; 2018 Aug; 101(5):1202-1211. PubMed ID: 29859793
[TBL] [Abstract][Full Text] [Related]
16. Helical tomotherapy for the treatment of anal canal cancer: a dosimetric comparison with 3D conformal radiotherapy.
Ugurluer G; Ballerini G; Moeckli R; Matzinger O; Bourhis J; Ozsahin M
Tumori; 2015; 101(3):268-72. PubMed ID: 25908035
[TBL] [Abstract][Full Text] [Related]
17. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
Salama JK; Mell LK; Schomas DA; Miller RC; Devisetty K; Jani AB; Mundt AJ; Roeske JC; Liauw SL; Chmura SJ
J Clin Oncol; 2007 Oct; 25(29):4581-6. PubMed ID: 17925552
[TBL] [Abstract][Full Text] [Related]
18. Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
Thind G; Johal B; Follwell M; Kennecke HF
Radiat Oncol; 2014 May; 9():124. PubMed ID: 24885554
[TBL] [Abstract][Full Text] [Related]
19. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer.
Glynne-Jones R; Meadows H; Wan S; Gollins S; Leslie M; Levine E; McDonald AC; Myint S; Samuel L; Sebag-Montefiore D;
Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):119-26. PubMed ID: 18472366
[TBL] [Abstract][Full Text] [Related]
20. Definitive chemoradiotherapy for anal canal cancer: single-center experience.
Tachibana I; Nishimura Y; Inada M; Fukuda K; Ishikawa K; Nishikawa T; Yokokawa M; Nakamatsu K; Kanamori S; Hida JI
Int J Clin Oncol; 2018 Dec; 23(6):1121-1126. PubMed ID: 29992389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]